Mr. Bivek Timalsina, a scientific team member of CHDS-Nepal, published a paper in Scientific Report, Nature Publication. This was the work that Mr. Timalsina did during his graduate studies in South Asian University, New Delhi.
This study identifies novel and broadly active maturation inhibitors (BVM analogs) that shown remarkable antiviral effect in HIV-1 subtype B and C.
Antiretroviral therapy has led to a profound improvement in the clinical care of HIV-infected patients. However, drug tolerability and the evolution of drug resistance have limited treatment options for many patients. Maturation inhibitors are a new class of antiretroviral agents for treatment of HIV-1. They act by interfering with the maturation of the virus by blocking the last step in Gag processing: the cleavage of the capsid-spacer peptide 1 (CA-SP1) intermediate to mature CA by the viral protease (PR). The first-in-class maturation inhibitor bevirimat (BVM) failed against a subset of HIV-1 isolates in clinical trials due to polymorphisms present in the CA-SP1 region of the Gag protein. Sequence analysis indicated that these polymorphisms are more common in non-clade B strains of HIV-1 such as HIV-1 clade C. Indeed, BVM was found to be ineffective against HIV-1 clade C molecular clones tested in this study. A number of BVM analogs were synthesized by chemical modifications at the C-28 position to improve its activity. The new BVM analogs displayed potent activity against HIV-1 clade B and C and also reduced infectivity of the virus. This study identifies novel and broadly active BVM analogs that may ultimately demonstrate efficacy in the clinic.
For more text:
COPYRIGHTS © 2016 Centre for Health and Disease Studies-Nepal (CHDS). ALL RIGHTS RESERVED.
Developed & Powered by Eknotech